The “Cherry” Release of O-RAN Open Software Moves the O-RAN Ecosystem Closer to Deployment in Mobile Networks Around the Globe
11.1.2021 19:51:00 EET | Business Wire | Press release
In December 2020, the O-RAN Software Community (OSC), working with the Linux Foundation, published its 3rd open software release within 18 months, dubbed “Cherry”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005829/en/
O-RAN Logical Architecture (Graphic: Business Wire)
Cherry moves the O-RAN ecosystem closer to commercial deployments in mobile networks around the globe. On top of new functions aligned with the latest O-RAN specifications, such as the E2, A1 and O1 interfaces, this release also features significant advancements in the end-to-end integration of O-RAN Architecture components to meet the needs of early adopters. In addition, new software projects in the area of Service Management and Orchestration (SMO) have been initiated to drive the development of auto-configuration and management of O-RAN elements.
The main use cases delivered in Cherry include:
- Policy based Traffic Steering using the A1 and E2 interfaces
- Automated Monitoring and Health check of selected components using the O1 interface
- Configuration, Fault and Performance Management Services aligned with OAM models and specifications newly approved by O-RAN
- Life Cycle Management Framework of rApps and xApps using SMO
- O-DU Low and High pairwise testing in O-RAN Software Community lab
- Simulators for testing and integration, such as E2, A1, Open Test Framework, and more
“It is gratifying to see the continued momentum of the OSC’s open-source O-RAN implementation,” said Jack Murray, co-chair of the OSC Technical Operating Committee (TOC) and Assistant Vice President of AT&T. “AT&T is proud to have continued its contributions to enable RAN AI/ML through the Near-Real Time RIC implementation, and to provide a platform for software testing and integration.”
“We are glad to see Cherry has made big progress by building on the base of Bronze,” said Chih-Lin I, the Co-Chair of O-RAN Technical Steering Committee. “It not only realizes more 3GPP-defined models, but also brings O-RAN defined interfaces including E2 and A1 closer to commercialization. More ML and AI technologies are implemented in the RIC, RICAPP and NRTRIC projects to push the traffic steering e2e use case forward, which makes it a more intelligent RAN. The newly created SMO project is also worth special mention for the quick momentum that it has gained in contributing to O-RAN automation and management within just 3 months.”
“Nokia continues to be very active in O-RAN and a major contributor to the O-RAN specifications,” said Pasi Toivanen, Head of Edge Cloud Platforms at Nokia. “With the Cherry Release, Nokia is contributing to the Near-Real-Time RIC and the E2 interface to advance RAN programmability, network openness, and the introduction of AI/ML intelligence to the network. The contributions also deliver increased robustness, more xApp framework capabilities and enhanced manageability of RIC platform and xApps.”
“Radisys continues to contribute actively to O-RAN standardization and open source development. In the Cherry release, Radisys enhanced O-DU L2 implementation to support UE attach, and integrated with PHY (O-DU Low) through the FAPI interface to enable end-to-end testing," said Ganesh Shenbagaraman, Head of Integrated Products and Ecosystems at Radisys.
“highstreet technologies substantially contributes to O1/OAM within both O-RAN and OSC,” said Alfons Mittermaier, Managing Director of highstreet technologies. “We expect the disaggregated O-RAN architecture to become a door opener for small and medium sized enterprises and will deploy the Cherry release in a 5G reference network in Berlin.”
“HCL has contributed to the O-RAN Software Community across different Work Groups starting with the Cherry Release,” said Ramesh Sriraman, the Head of Telecom Center of Excellence at HCL. “We Improved Near-Real-Time RIC platform CI/CD deployment, automation, performance & scale; introduced AI/ML intelligence to RAN network via xApps; and contributed the initial implementation of the O-RAN O1 interface in the O-DU. It is a great honor for HCL to develop together with the OSC team.”
To learn more about the O-RAN Software Community Cherry release please read this O-RAN Blog post, and to access the code, check out the O-RAN Software Community website.
The O-RAN Software Community continues to be open to any participants that want to get involved in the creation of software for future RAN – for more details please visit https://www.o-ran.org/software.
About O-RAN ALLIANCE
The O-RAN ALLIANCE is a world-wide community of more than 240 mobile operators, vendors, and research & academic institutions operating in the Radio Access Network (RAN) industry. As the RAN is an essential part of any mobile network, the O-RAN ALLIANCE’s mission is to re-shape the industry towards more intelligent, open, virtualized and fully interoperable mobile networks. The new O-RAN standards will enable a more competitive and vibrant RAN supplier ecosystem with faster innovation to improve user experience. O-RAN based mobile networks will at the same time improve the efficiency of RAN deployments as well as operations by the mobile operators. To achieve this, the O-RAN ALLIANCE publishes new RAN specifications, releases open software for the RAN, and supports its members in integration and testing of their implementations.
For more information please visit www.o-ran.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005829/en/
Contact information
O-RAN ALLIANCE PR Contact
Zbynek Dalecky
pr@o-ran.org
O-RAN ALLIANCE e.V.
Buschkauler Weg 27
53347 Alfter/Germany
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
